Isooxazol derivatives as antagonists of lysophosphatidic acid Receptors, which includes Pharmaceutical Composition and its use in the treatment of diseases mediated by Physiological Activity of LPA.

摘要

This document describes compounds that are resistant to stereoisomers. This document also describes the pharmaceutical ingredients and drugs, including the compounds described in this document, as well as the conditions or diseases under which these antitube drugs are used to treat LPA or LPA mediated alone or together with other compounds. Claim 1: a compound whose structure is formula (1) or a pharmaceutically acceptable salt, wherein R1 is - CO2H, co2rd, CN, tetrazolilo, O-C (= O) nso2r10; RD is h or C1-4 tar; L1 is C1-6 missing or tar; R3 is h, C1-4 tar, cyclo-6;or C1-4 fluoroalkyl; R7 is H or C1-4 alkyl; R8 is H, C1-4alkyl, or C1-4 fluoroalkyl; R10 is C1-6alkyl, fluoroC1-6alkyl, C3-6cycloalkyl, or substituted or unsubstituted phenyl; RA, RB, and RC are each independently selected from H, F, CI, Br, I, -CN, -OH, C1-4alkyl, C1-4 fluoroalkyl, C1-4 fluoroalkoxy, C1-4alkoxy, and C1-4 heteroalkyl; m is 0, 1, or 2; n is 0, 1, or 2; p is 0, 1, or 2.